**Laurence Watts | Gilmartin Group LLC**
Thank you, operator.
Joining us on the call today from Immuneering are Chief Executive Officer Ben Zeskind; Chief Scientific Officer Brett Hall; Chief Medical Officer Igor Matushansky; Chief Accounting Officer and Treasurer Mallory Morales; and E. B. Brakewood, our Chief Business Officer.
During this call, management and our two investigators will refer to slides that you can find in the updated version of our corporate deck, available in PDF format on our Investor Relations website.
Throughout this call, management will be making forward-looking statements, including those related to our Phase IIa trial of atebimetinib, the timing of additional data from the study, and the company’s development plans.
Please note that our actual results and the timing of events could differ materially from those anticipated in these forward-looking statements due to various risks and uncertainties. Factors that could cause actual results to differ are described in the company’s securities filings, including its annual report on Form 10-K and quarterly reports on Form 10-Q.
Immuneering undertakes no duty or obligation to update any forward-looking statements as a result of new information or future events.
https://seekingalpha.com/article/4842890-immuneering-corporation-imrx-q3-2025-earnings-call-transcript?source=feed_all_articles
